Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-02-03
2001-03-20
Gerstl, Robert (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S538000, C514S562000, C560S009000, C562S426000, C549S039000
Reexamination Certificate
active
06204288
ABSTRACT:
BACKGROUND OF THE INVENTION
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily of ligand-activated transcription factors. Three subtypes of PPARs have been cloned from the mouse and human: i.e., PPAR&agr;, PPAR&ggr; and PPAR&dgr;. The PPARs are believed to play a role in the regulation of lipid metabolism. They can be activated by high concentration of fatty acids and have been shown to regulate the expression levels of fatty acid binding proteins or enzymes involved in fatty acid oxidation.
It has previously been discovered that a certain class of thiazolidinediones are selective PPAR&ggr; agonists (see, Willson et. al.,
J. Med. Chem.
(1996) 39:665-668). Thiazolidinediones are a class of oral insulin-sensitizing agents that improve glucose utilization without stimulating insulin release. For instance, U.S. Pat. No. 4,287,200 discloses certain thiazolidine derivatives having the ability to lower blood glucose sugar levels. In addition, U.S. Pat. No. 4,572,912 discloses thiazolindinedione derivatives having the ability to lower blood lipid and blood sugar levels. These compounds were shown to have the ability to decrease the levels of blood lipid peroxides, blood triglycerides and blood cholesterol.
Moreover, U.S. Pat. No. 5,338,855 discloses thiazolidine derivatives containing a quinone moiety. These compounds were shown to have the ability to reduce insulin resistance in the peripheral tissues and possess the ability to suppress hepatic gluconeogenesis in the liver.
In addition to being anti-diabetic agents which can lower the concentration of glucose and lipids in the blood, U.S. Pat. No. 5,594,015 discloses thiazolidine derivatives as being effective in the treatment of hyperproliferation of epithelial cell conditions, such as psoriatic activity.
The anti-diabetic effect of the thiazolidinediones and their PPAR&ggr; agonist activity has implicated PPAR&ggr; as the molecular target for the anti-diabetic effects of thiazolidinediones. PPAR&ggr; is predominantly expressed in adipose tissue and has been implicated as a master regulator of adipocyte differentiation in pre-adipose cell lines.
In view of the role PPAR&ggr; plays in regulation of lipid metabolism and the antagonistic behavior of thiazolidinediones, there remains a need in the art for new thiazolindinedione derivatives and more effective therapies for diabetes and other ailments. The present invention fulfills these and other needs.
SUMMARY OF THE INVENTION
This invention provides new thiazolindinedione derivatives. As such, in one aspect, the present invention provides compounds of Formula I:
In Formula I, R
1
and R
2
are hydrogen. In an alternative embodiment, R
1
and R
2
together with the sulfurs to which they are bound join to form a 1,2-dithiolane ring. X, in Formula I, is functional group including, but not limited to O, NR, C(O)O, OC(O)O and C(O)NR, wherein R is a functional group including, but not limited to, hydrogen and optionally substituted (C
1
-C
6
)allyl. Y, in Formula I, is a functional group including, but not limited to, O, S and NR
3
, wherein R
3
is a functional group including, but not limited to, hydrogen and optionally substituted (C
1
-C
6
)alkyl. In Formula I, the index “n” is an integer from 2 to 14; the index “m” is an integer from 0 to 14; the index “q” is an integer from 0 to 1; and the index “t” is an integer from 0 to 1.
In another embodiment, the present invention provides a compound of Formula II:
In Formula II, R
1
and R
2
are hydrogen. In an alternative embodiment, R
1
and R
2
together with the sulfurs to which they are bound join to form a 1,2-dithiolane ring. X, in Formula II, is functional group including, but not limited to O, NR, C(O)O, OC(O)O and C(O)NR, wherein R is a functional group including, but not limited to, hydrogen, optionally substituted (C
1
-C
6
)alkyl and optionally substituted aryl. Y, in Formula II, is a functional group including, but not limited to, O, S and NR
3
, wherein R
3
is a functional group including, but not limited to, hydrogen and optionally substituted (C
1
-C
6
)alkyl. R
4
, in Formula II, is a functional group including, but not limited to, hydrogen, halogen, optionally substituted (C
1
-C
6
)alkyl and optionally substituted (C
1
-C
6
)alkoxy. R
5
, in Formula II, is a functional group including, but not limited to, hydrogen and optionally substituted (C
1
-C
6
)alkyl. In Formula II, the index “n” is an integer from 2 to 14; the index “m” is an integer from 0 to 14; and the index “q” is an integer from 0 to 1.
In another aspect, the present invention relates to a pharmaceutical composition comprising a compound of the Formula I wherein R, R
1
, R
2
X, Y, R
3
n, m, q and t have the same meaning as defined above, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical acceptable carrier.
In another aspect, the present invention relates to a pharmaceutical composition comprising a compound of the Formula II wherein R, R
1
, R
2
X, Y, R
3
, R
4
R
5
, n, m, and q have the same meaning as defined above, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical acceptable carrier.
In yet another aspect, the present invention relates to a method of treating a PPAR&ggr; mediated disease, comprising administering a therapeutically effective amount of a compound of Formulae I, II or mixtures thereof, to an individual suffering from a PPAR&ggr; mediated disease. In other aspects, this invention provides methods for synthesizing the compounds of Formulae I and II.
REFERENCES:
patent: 4287200 (1981-09-01), Kawamatsu et al.
patent: 4572912 (1986-02-01), Yoshioka et al.
patent: 4918091 (1990-04-01), Cantello et al.
patent: 5338855 (1994-08-01), Yoshioka et al.
patent: 5594015 (1997-01-01), Kurtz et al.
patent: 5661168 (1997-08-01), Panetta et al.
patent: 6013663 (2000-01-01), Fujita et al.
patent: WO 97/31907 (1997-09-01), None
Schweizer, E., et al., “Reactions of Phosphorus Compounds. XIX. Reactions of 3-(o-Formylphenoxy)propyltriphenylphosphonium Bromide and 3-(p-Formylphenoxy)propyltriphenylphosphonium Bromide,”J. Org. Chem., 34(1):207-212 (1969).
Newman, et al., “Thiophenols from Phenols: 2-Naphthalenthiol,”Organic Synthesis, 51:139-142 (1971).
Barry, “Properties That Influence Percutaneous Absoprtion,”Dermatological Formulations, Percutaneous Absorption, 18:181-185 (1983).
Nate, H., et al., “Synthesis of 2-Phenylthiazolidine Derivatives as Cardiotonic Agents. II. 2-(Phenylpiperazinoalkoxyphenyl)thiazolidine-3-thiocarboxamides and the Corresponding Carboxamides,”Chem. Pharm. Bull., 35(6):2394-2411 (1987).
Calmes, M., et al., “Supramolecular Asymmetric Induction: A New Concept Applied to the Supported Enantioselective Synthesis of &agr;-Amino Acids,”Tetrahedron, 46(17):6021-6032 (1990).
Hulin B., et al., “Novel Thiazolidine-2,4-diones as Potent Euglycemic Agents”,J. Med. Chem., 35(10):1853-1864 (1992).
Suzuki, Y. J., et al., “An Antioxidant Activities of Dihydrolipoic Acid and its Structural Homologues”,Free Rad. Res. Comms., 18(2): 115-122 (1993).
Lehmann, J.M., et al., “An Antidiabetic Thiazolidnedione is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor &ggr;(PPAR &ggr;),”J. Biol. Chem., 270(22):12953-12956 (1995).
Wilson, T., et al., “The Structure—Activity Relationship Between Peroxisome Proliferator-Activated Receptor &ggr; Agonism and the Anithyperglycemic Activity of Thiazolidinediones,”J. Med. Chem., 39(3): 665-668 (1996).
Perlmann & Evans, “Nuclear Receptors in Sicily: All in the Famiglia,”Cell, 90:391-397(1997).
Tomkinson, Nicholas, C.O., et al., “Solid-phase synthesis of hybrid thiazolidinedione-fatty acid PPAR&ggr; ligands,”Bioorganic&Medicinal Chemistry Letters, 7(19):2491-2496 (1997).
Nolte, Robert T., et al., “Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-&ggr;,”Nature, 395:137-143 (Sep. 10, 1998).
Henke, Brad R., et al., “N-(2-benzoylphenyl)-l-tyrosine PPAR&ggr; agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents,”J. M
Avery Mitchell A.
Pershadsingh Harrihar A.
Gerstl Robert
The University of Mississippi
Townsend and Townsend and Crew
LandOfFree
1,2-dithiolane derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,2-dithiolane derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,2-dithiolane derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2478777